0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
00:00
00:00
00:00
 
This video file cannot be played.(Error Code: 224003)

Update on Predatory "Cell Therapy" Clinics

Show Description +

How has action from FDA reduced the number of predatory "cell therapy" clinics peddling cures for various ocular conditions? Guest Ajay Kuriyan, MD, sits down with host María H. Berrocal, MD, to explore why these clinics are so dangerous, what has changed since the last time these clinics were examined, and how retina specialists can advocate for their patients' safety.

Posted: 5/28/2025

Up Next

Is Teleretinal Screening for DR and DME Effective?

María H. Berrocal, MD; and Christina Y. Weng, MD, MBA


Clinical Minute: Retina: Features Associated with Progression to GA in AMD

Maria Berrocal, MD, and Usha Chakravarthy, MD, PhD

Clinical Minute: Retina: Simultaneous UWF Imaging with OCT and FFA/ICGA

Paulo E. Stanga, MD, and Maria H. Berrocal, MD

Clinical Minute: Retina: AI in ROP

María Berrocal, MD and Darius Moshfeghi, MD

Clinical Minute: Retina: The Mac Tel Project

María Berrocal, MD and Lihteh Wu, MD

Clinical Minute: Retina: The Future of the PDS with Ranibizumab

Dante Pieramici, MD and María Berrocal, MD

Clinical Minute Retina: PPV for VH Secondary to RVO

Ramin Tadayoni, MD, PhD and Carl Regillo, MD

GATHER2 Data at 1 and 2 Years

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Biosimilars in Retina

Ramin Tadayoni, MD, PhD, and Prof. Frank Holz

Meta-analysis of Anti-VEGF Agents in Wet AMD Therapy

Ramin Tadayoni, MD, PhD and Jean-Francois Korobelnik, MD, PhD

PPV vs Conventional Therapy for PDR

María H. Berrocal, MD, and Ramin Tadayoni, MD, PhD

GA Therapy After the Newest DERBY/OAKS Data

Eleonora Lad, MD, PhD and Ramin Tadayoni, MD, PhD

Protocol AC: Step Therapy in DME

Chirag D. Jhaveri, MD; and Prof. Ramin Tadayoni

TRUCKEE Study Data

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Pegcetacoplan Phase 3 Data

Ramin Tadayoni, MD, PhD and Caroline Baumal, MD

Rates of Endophthalmitis in a Nationwide Study

Ramin Tadayoni, MD, PhD; and Catherine Creuzot-Garcher, MD

Why Some Clinical Trials Succeed Where Others Do Not

Ramin Tadayoni, MD, PhD; and Peter Kaiser, MD

AI in Retinal Imaging

Ramin Tadayoni, MD, PhD; Ursula Schmidt-Erfurth, MD

Intraoperative OCT: From Concept to Execution

Ramin Tadayoni, MD, PhD; and Cynthia Toth, MD

AI in the Modern Age of Retina

Anat Loewenstein MD, MHA

The History of ILM Staining

Ramin Tadayoni MD, PhD; and Kazuaki Kadonosono, MD, PhD

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

Growing Comfortable with the Suprachoroidal Space

Maria Berrocal, MD, and Robert L. Avery, MD

Update on Predatory "Cell Therapy" Clinics

How has action from FDA reduced the number of predatory "cell therapy" clinics peddling cures for various ocular conditions? Guest Ajay Kuriyan, MD, sits down with host María H. Berrocal, MD, to explore why these clinics are so dangerous, what has changed since the last time these clinics were examined, and how retina specialists can advocate for their patients' safety.

Posted: 5/28/2025


Please log in to leave a comment.